Flash Finance

Kopran LimitedKOPRANCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹271.15
MCap ₹1,310 Cr · P/E 39.0
Kopran Limited — Stock analysis & AI research Kopran Limited — Seasonality — best & worst months Kopran Limited — Technical setup — score, trend, support & resistance Kopran Limited — Live exchange announcements
📈 Strong Trend Stocks (ADX > 25)📈 Bullish EMA Alignment📈 Relative Strength Leaders📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks📈 Accumulation (OBV Rising) 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹63 Cr
Sales · Jun 2026
+22.3% YoY
₹8 Cr
Operating Profit · Jun 2026
+66.7% YoY
13.5%
OPM % · Jun 2026
+36.4% YoY
₹7 Cr
Net Profit · Jun 2026
+91.1% YoY
—
EPS · Jun 2026

📝 Kopran Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Kopran Limited reported revenue of ₹63 crore for the quarter ended June 2026 (Q1 FY27), up 22.3% from ₹51 crore in the same quarter last year, and down 46.8% sequentially over the March 2026 quarter.

Net profit rose 91.1% year-on-year to ₹7 crore, from ₹4 crore.

Operating profit stood at ₹8 crore — an operating margin (OPM) of 13.5%, compared with 9.9% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Kopran Limited posted revenue of ₹306 crore, a decline of 97.5% over FY25, with a net profit of ₹30 crore (down 97.4% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹317 crore with a net profit of ₹34 crore.

Valuation snapshot

At the current price of ₹271.15, KOPRAN has a market capitalisation of ₹1,310 crore and a trailing P/E of about 39.0.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 41.82%, foreign institutional investors (FIIs) 0.91%, public shareholders 57.27% of Kopran Limited.

Promoter holding slipped from 44.43% to 41.82% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,310 Cr
Current Price ?
₹271.1
P/E ?
38.99above ind
Industry P/E ?
37.20
P/B ?
2.92
P/S ?
4.13
P/FCF ?
327.59
Enterprise Value ?
₹1,356 Cr
EV/EBITDA ?
27.39
PEG ?
N/A
Earnings Yield ?
3.3%
Dividend Yield ?
1.10%
Profitability & Returns
Sales (TTM) ?
₹317 Cr
OPM ?
15.6%
Profit after tax (TTM) ?
₹34 Cr
EPS (TTM) ?
₹6.95
ROCE ?
9.0%
ROE ?
7.5%
ROA ?
5.5%
Growth
Sales — latest qtr ?
₹63 Cr
PAT — latest qtr ?
₹7 Cr
YoY qtr sales growth ?
22.3%
YoY qtr profit growth ?
91.1%
Sales growth (3y) ?
4%
Sales growth (5y) ?
7%
Profit growth (3y) ?
-1%
Profit growth (5y) ?
5%
Financial Health
Debt ?
₹46 Cr
Debt to Equity ?
0.10
Interest Coverage ?
9.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
41.82%
Change in promoter holding ?
-2.61%
Pledged percentage ?
N/A
Market
Return 3 months ?
33.2%
Return 6 months ?
70.2%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 80669982914,961747,1947651429411863 +22.3% -46.8%
Operating Profit 7191215528101,140125-318278 +66.7% -68.2%
Other Income 21618212175220013 +62.1% +190.4%
Interest 1111269199111111 +18.8% +5.6%
Depreciation 111111201133111111 +10.5% +0.2%
Profit Before Tax 801311215519983125-516259 +90.6% -65.0%
Net Profit 6011915425774194-412197 +91.1% -64.1%
EPS 1.140.032.211.773.180.881.371.541.780.73-0.832.513.88— — —
OPM % 9.2% 1.2% 8.8% 14.7% 16.9% 10.6% 13.2% 15.8% 16.2% 9.9% -7.6% 18.8% 22.5% 13.5% +36.4% -40.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹12,304 Cr ₹306 Cr ₹317 Cr -97.5%
Operating Profit ₹1,690 Cr ₹46 Cr ₹50 Cr -97.3%
OPM % 13.74% 15.09% 15.62% +9.8%
NPM % 9.59% 9.95% 10.60% +3.8%
Other Income ₹290 Cr ₹3 Cr ₹5 Cr -98.8%
Depreciation ₹255 Cr ₹5 Cr ₹5 Cr -98.0%
Interest ₹170 Cr ₹4 Cr ₹4 Cr -97.5%
EBIT ₹1,435 Cr ₹41 Cr ₹44 Cr -97.1%
PBT ₹1,554 Cr ₹40 Cr ₹45 Cr -97.4%
Tax ₹374 Cr ₹10 Cr ₹11 Cr -97.3%
Net Profit ₹1,181 Cr ₹30 Cr ₹34 Cr -97.4%
EPS ₹5.57 ₹6.29 ₹5.56 +12.9%
Material Cost ₹7,039 Cr ₹166 Cr ₹180 Cr -97.6%
Employee Cost ₹1,393 Cr ₹33 Cr ₹34 Cr -97.6%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 48484848 +0.0%
Reserves 347369383400 +4.4%
Borrowings 28234546 +2.2%
Other Liabilities 827170112 +60.0%
Total Liabilities 506511546606 +11.0%
Fixed Assets 47526189 +45.9%
CWIP 4570 -100.0%
Investments 260261263265 +0.8%
Other Assets 195193215252 +17.2%
Total Assets 506511546606 +11.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 17352330 +30.4%
Cash from Investing Activity 10-6-15-30 -100.0%
Cash from Financing Activity -26-246-19 -416.7%
Net Cash Flow 1514-19 -235.7%
Free Cash Flow 112464 -33.3%
CFO/OP 83%121%86%71% -17.4%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 11295124158 +27.4%
Inventory Days 9878129141 +9.3%
Days Payable 12882108162 +50.0%
Cash Conversion Cycle 8291145137 -5.5%
Working Capital Days 116104114109 -4.4%
ROCE % 9%11%9%9% +0.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Sep 2026 % Chg
Promoters 44.43%44.43%44.43%44.43%41.82% -5.9%
FIIs 0.76%0.60%0.36%0.57%0.91% +59.6%
DIIs 0.00%0.00%0.00%0.00%— —
Public 54.81%54.99%55.21%55.01%57.27% +4.1%
No. of Shareholders 60,19462,22260,88658,63952,924 -9.7%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was Kopran Limited's revenue in Q1 FY27?
Kopran Limited reported revenue of ₹63 crore for the quarter ended June 2026 (Q1 FY27), up 22.3% from ₹51 crore in the same quarter last year, and down 46.8% sequentially over the March 2026 quarter.
What was Kopran Limited's net profit in Q1 FY27?
Net profit rose 91.1% year-on-year to ₹7 crore, from ₹4 crore.
What is KOPRAN's market capitalisation and P/E ratio?
At the current price of ₹271.15, KOPRAN has a market capitalisation of ₹1,310 crore and a trailing P/E of about 39.0.
Who owns Kopran Limited? (shareholding pattern)
As of Sep 2026, promoters held 41.82%, foreign institutional investors (FIIs) 0.91%, public shareholders 57.27% of Kopran Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI